Great data! Huge potential! (Too bad it failed the primary endpoint)
It’s not unusual for a biotech to cherry pick the most promising bits of data from a clinical study and lead with its best results …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
